1Kruger, A.The limits of normality in elderly patients. Clinics Haematol 1987; 1: 271–89.Google ScholarPubMed

2Carpenter, MA, Kendall, RG, O'Brien, AEet al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 1992; 49: 119–21.CrossRefGoogle ScholarPubMed

3Makinodan, T, Kay, MMB. Age influence on the immune system. In: Kunkel, H, Dixon, H eds. Advances in immunology, volume 29. New York: Academic Press, 1980: 289–330.Google Scholar

4Jacobs, A.Genetic lesions in preleukaemia. Leukaemia 1991; 5: 277–82.Google Scholar

5Martineau, M, Potter, AM, Watemore, AE, Secker-Walker, LM. Loss of the Y chromosome from normal and neoplastic bone marrows. London: International Society of Haematology, 24th meeting, 1992: 414.Google Scholar

6Means, RT, Krantz, SB.Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992; 80: 1639–47.CrossRefGoogle Scholar

7Biregegard, G, Gudbjronsson, B, Hallgren, R, Wide, L.Anaemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. Contrib Nephrol 1991; 88: 295–303.Google Scholar

8Ludwig, H, Fritz, E, Kotzmann, H, Hocker, P, Gisslinger, H, Barnas, U.Erythropoietin treatment of anaemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–99.CrossRefGoogle ScholarPubMed

9Steiner, RW, Coggins, C, Carvalho, ACA.Bleeding time in uraemia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7: 107–17.Google Scholar

10Eschbach, JW, Kelly, MR, Haley, NR, Abels, RI, Adamson, JW.Treatment of the anaemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–63.CrossRefGoogle ScholarPubMed

11Marcus, DL, Freedman, ML.Clinical disorders of iron metabolism in the elderly. Clinics Geriatr Med 1985; 1: 729–45.CrossRefGoogle ScholarPubMed

12Jensen, BM, Sando, SH, Grandjaen, P, Wiggers, P, Dalhoj, J.Screening with zinc protoporphyrin for iron deficiency anemia. JAMA 1990; 36: 846–48.Google Scholar

13Bennett, JM, Catovsky, D, Daniel, M-Tet al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–99.CrossRefGoogle ScholarPubMed

14White, AD, Culligan, DJ, Hoy, TG, Jacobs, A.Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). Br J Haematol 1992; 81: 499–502.CrossRefGoogle ScholarPubMed

15Van den Berghe, H.The 5q– syndrome. Scand J Haematol 1986; 36: 78–81.Google Scholar

16Boogaerts, MA, Nelissen, V, Roelant, C, Goossens, W.Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55: 217–27.Google Scholar

17Mufti, GJ. A guide to risk assessment in the primary myelodysplastic syndrome. In: Koeffler, HP ed. Myelodysplastic syndromes, haematology/ oncology clinics of North America. Philadelphia: WB Saunders, 1992: 587–606.Google Scholar

18Armitage, JO, Dick, FR, Needleman, SW, Burns, CP.Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 1981; 65: 601–605.Google ScholarPubMed

19Huang, E, Nocka, K, Beier, DRet al. The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990; 63: 225–33.CrossRefGoogle Scholar

20Goselink, HM, Williams, DE, Fibbe, WEet al. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. Blood (in press).Google Scholar

21Feldman, AR, Kessler, L, Myers, MH, Naughton, MD.The prevalence of cancer. Estimates based on the Connecticut Tumour Registry. N Engl J Med 1986; 315: 1394–97.CrossRefGoogle Scholar

22Giannoulis, N, Ogier, C, Hast, R.Difference between young and old patients in characteristics of leukaemic cells: older patients have cells growing excessively in vitro, with low antigenicity despite high HLA-DR antigens. Am J Hematol 1984; 16: 113–21.Google Scholar

23Liu, Yin JA, Johnson, PRE, Davies, JM, Flanagan, NG, Gorst, DW, Lewis, MJ.Mitozanthrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991; 79: 415–20.Google Scholar

24Hanslip, JI, Swansbury, GJ, Min, T, Matutes, E, Morilla, R, Catovsky, D. The significance of trilineage myelodysplasia (TMDS) in acute myeloid leukaemia (AML): a study of clinical features, immunophenotype and karyotype in 185 patients. London: International Society of Haematology, 24th Meeting, 1992: 246.Google Scholar

25Rees, JKH, Gray, RG, Swirsky, D, Hayhoe, FGJ.Principal results of the Medical Research Council's 8th acute myeloid trial. Lancet 1986; ii: 1236–41.CrossRefGoogle Scholar

26Lowenberg, B, Zittoun, R, Kerkhofs, Het al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: a randomised phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia group. J Clin Oncol 1989; 7: 1268–74.CrossRefGoogle Scholar

27Reiffers, J, Huguet, F, Stoppa, AM, Michallet, M, Hurteloup, P.Intensive induction chemotherapy in elderly patients. Br J Haematol 1992; 82: 175–77.Google Scholar

28De Wolf, JTM, Hendriks, DW, Egger, RC, Esselink, MT, Halie, MR, Vellenga, E.Alpha-interferon for intractable pruritis in polycythaemia vera. Lancet 1991; 337: 241.Google Scholar

29Jabaily, J, Iland, H, Laszlo, Jet al. Neurological manifestations of essential thrombocythemia. Ann Intern Med 1983; 99: 513–18.Google Scholar

30Preston, FE, Emmanual, I, Winfield, D, Malia, R.Essential thrombocytaemia and peripheral gangrene. Br J Med 1974; 3:548–52.CrossRefGoogle Scholar

31Singh, AK, Wetherley-Mein, G.Microvascular occlusive lesions in primary thrombocythaemia. Br J Haematol 1977; 36: 553–64.CrossRefGoogle ScholarPubMed

32Reilly, JT.Pathogenesis of idiopathic myelofibrosis: role of growth factors. J Clin Pathol 1992; 45: 461–64.CrossRefGoogle ScholarPubMed

33Binet, JL, Auquier, A, Dighiero, Get al. A new prognostic classification of chronic lymphatic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.Google Scholar

34Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomised, controlled clinical trial. N Engl J Med 1988; 319: 902–907.CrossRefGoogle Scholar

35Petersen, BA, Pajak, TE, Cooper, MRet al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982; 66: 889–98.Google Scholar

36Newell, GR, Cabanillas, FG, Hagemeister, FJ, Butler, JJ.Incidence of lymphoma in the US classified by the Working Formulation. Cancer 1987; 59: 857–61.Google Scholar

37Rappaport, H, Winter, WJ, Hicks, EB.Follicular lymphoma. A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9: 792–96.3.0.CO;2-B>CrossRefGoogle Scholar

38Stansfeld, AG, Diebold, J, Noel, Het al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–93.Google Scholar

39Vose, JM, Armitage, JO, Weisenberger, DDet al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–44.Google Scholar

40Sonneveld, P, Michials, JJ.Full dose chemotherapy in elderly patients with non-Hodgkins lymphoma: a feasibility study using mitozanthrone containing regime. Br J Cancer 1990; 62: 105–108.CrossRefGoogle Scholar

41Watkin, SW, Green, JA.Non Hodgkin's lymphoma– a four-drug regimen suitable for elderly patients with advanced disease. Acta Oncol 1990; 29: 733–37.Google Scholar

42Gams, RA, Steinberg, J, Posner, L.Mitozanthrone in malignant lymphoma. Semin Oncol 1984; 11: 47–49.Google Scholar

43Crawford, J, Eye, MK, Cohen, HJ.Evaluation of monoclonal gammopathies in the ‘well’ elderly. Am J Med 1987; 82: 39–45.Google Scholar

44Belch, A, Shelley, W, Bergsagel, Det al. A randomised trial of maintenance versus no maintenance melphalan and prednisolone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94–99.CrossRefGoogle Scholar

45Boccadoro, M, Pileri, A.Standard chemotherapy for myelomatosis: an area of great controversy. Hematol/Oncol Clinics North Am 1992; 6: 371–82.CrossRefGoogle ScholarPubMed

46Barlogie, B, Smith, L, Alexanian, R.Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–56.Google Scholar

47Alexanian, R, Dreicer, R.Chemotherapy for multiple myeloma. Cancer 1984; 53: 583–88.Google Scholar